(KOD) – StreetInsider.com Reports
-
Kodiak Sciences Inc. (KOD) Misses Q4 EPS by 36c
-
Kodiak Sciences Inc. (KOD) PT Lowered to $3 at UBS
-
Goldman Sachs Reinstates Kodiak Sciences Inc. (KOD) at Sell, 'Cautious on the tarcocimab reboot'
-
CapitalOne Upgrades Kodiak Sciences Inc. (KOD) to Overweight
-
Kodiak Sciences Inc. (KOD) Tops Q3 EPS by 26c
-
Kodiak Sciences Inc. (KOD) Reports Topline Data for tarcocimab tedromer
-
Kodiak Sciences Inc. (KOD) Misses Q2 EPS by 38c
-
UBS Downgrades Kodiak Sciences Inc. (KOD) to Neutral
-
Chardan Capital Markets Downgrades Kodiak Sciences Inc. (KOD) to Neutral
-
Kodiak Sciences Inc. (KOD) PT Lowered to $2 at Barclays
-
JPMorgan Downgrades Kodiak Sciences Inc. (KOD) to Underweight
-
Jefferies Downgrades Kodiak Sciences Inc. (KOD) to Hold
-
CapitalOne Downgrades Kodiak Sciences Inc. (KOD) to Equal-weight
-
Kodiak Sciences Inc. (KOD) falls 50% on plan to discontinue further development of tarcocimab.
-
Kodiak Sciences (KOD) Reports Topline Results from its Phase 3 Studies of Tarcocimab Tedromer
-
Kodiak Sciences Inc. (KOD) Files $350M Mixed Shelf
-
Kodiak Sciences Inc. (KOD) PT Lowered to $10 at JPMorgan
-
Kodiak Sciences (KOD) Expands Development Pipeline with Treatment of First Patient in Phase 1 Clinical Study of KSI-501, an Investigational Bispecific Antibody Biopolymer Conjugate for Retinal Disease
-
Kodiak Sciences Inc. (KOD) PT Lowered to $12 at JPMorgan
-
CapitalOne Starts Kodiak Sciences Inc. (KOD) at Overweight
-
Kodiak Sciences Inc. (KOD) PT Lowered to $6 at Citi
-
Kodiak Sciences Inc. (KOD) PT Lowered to $8 at Goldman Sachs
-
Kodiak Sciences Inc. (KOD) PT Lowered to $13 at JPMorgan
-
Kodiak Sciences Inc. (KOD) PT Raised to $8 at Citi
-
Kodiak Sciences Inc. (KOD) Reports Positive Topline Results from BEACON Phase 3 Study of Tarcocimab Tedromer
-
Citi Downgrades Kodiak Sciences Inc. (KOD) to Sell
-
Increasing unusual option volume: KOD GETY FTI FAZE RMO
-
Kodiak Sciences (KOD) Gains Following Market Chatter
-
Kodiak Sciences Inc. (KOD) PT Lowered to $5 at Barclays
-
Kodiak Sciences Inc. (KOD) PT Lowered to $12 at Morgan Stanley
-
Kodiak Sciences Inc. (KOD) PT Lowered to $15 at UBS
-
Kodiak Sciences Inc. (KOD) PT Lowered to $75 at Roth Capital
-
Kodiak Sciences Inc. (KOD) PT Lowered to $6 at Barclays
-
Kodiak Sciences Inc. (KOD) PT Lowered to $17 at Morgan Stanley
-
Kodiak Sciences Inc. (KOD) PT Lowered to $7 at Goldman Sachs
-
UPDATE: JPMorgan Downgrades Kodiak Sciences Inc. (KOD) to Neutral
-
Kodiak Sciences Inc. (KOD) PT Lowered to $12 at Citi
-
Kodiak Sciences Inc. (KOD) PT Lowered to $35 at Truist Securities; 'Buyers on Weakness'
-
Pre-Open Stock Movers 02/23: (REGI) (SKIN) (CDNS) Higher; (KOD) (RXT) (MGNI) Lower (more...)
-
Kodiak Sciences (KOD) Plunges Over 70% as KSI-301 Fails to Meet Primary Efficacy Endpoint
-
Kodiak Sciences Inc. (KOD) Reports Phase 2b/3 Study of KSI-301 Did Not Meet Primary Endpoint
-
Kodiak (KOD) Reiterated at Buy by Truist Securities, Analyst Believes wAMD Trial Will be Successful, Models Peak Sales of $2.7B
-
UPDATE: Goldman Sachs Starts Kodiak Sciences Inc. (KOD) at Neutral
-
Kodiak Sciences Inc. (KOD) PT Lowered to $50 at Barclays
-
Kodiak Sciences Inc. (KOD) Completes Enrollment in GLEAM and GLIMMER Phase 3 Trials
-
Kodiak Sciences Inc. (KOD) PT Lowered to $121 at UBS
-
UPDATE: JPMorgan Upgrades Kodiak Sciences Inc. (KOD) to Overweight
-
Kodiak Sciences Inc. (KOD) PT Lowered to $70 at Citi
-
Kodiak Sciences Inc. (KOD) PT Lowered to $124 at JPMorgan
-
Kodiak Sciences Inc. (KOD) PT Raised to $114 at Citi
Back to KOD Stock Lookup